McKesson Ventures
  • Portfolio
  • News
    • In the News
    • Press Releases
  • Team
  • About Us
    • Our Approach
    • About McKesson
    • Contact Us

Digital Health Intervention for Asthma: Patient-Reported Value and Usability

by McKesson Ventures | Jun 30, 2018 | Portfolio News

A report on a 12-month study evaluating patient-reported effectiveness and value of Propeller Health’s electronic inhaler sensor has been published by JMIR Publications. Doctors collaborating on this study represented five different organizations: Dignity Health –...

With $20 Million in Funding, Propeller Health Partners With Aptar Pharma To Make Digital Medicines

by McKesson Ventures | Jun 13, 2018 | Portfolio News

Propeller Health has partnered up with Aptar Pharma, which last year generated $800 million selling drug dispensation devices such as inhalers and injectors to drug companies. Aptar and Propeller Health will digitally connect these devices to Propeller’s software via...

Propeller Health Raises Strategic Investment from McKesson Ventures

by McKesson Ventures | Jun 11, 2018 | Press Releases

Propeller Health announced today that McKesson Ventures has contributed an undisclosed amount to its $20 million strategic funding round. The funding will allow Propeller Health to continue developing connected medicines for the treatment of chronic respiratory...
Page 4 of 4«1234

Recent Posts

  • Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care
  • Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
  • Lynx Closes $27 Million Oversubscribed Series A, Aims to Revolutionize Healthcare Payments and Administration
  • HarmonyCares Announces 2023 Results for its High Needs REACH ACO
  • Reimagine Care and Memorial Hermann Health System Unveil Expanded On-Demand Cancer Care Partnership
McKesson Ventures

One Post Street, 21st Floor
San Francisco, CA 94104
USA

Contact Us

Cookie Settings

In the News

Aster Insights Announces Research Partnership with FDA to Study the Effects of Patient Demographics on Diagnostic Indicators Used for Checkpoint Inhibitor Therapy

Emerging Leaders 2024: Carrie Williams, McKesson Ventures

Forbes’ 2024 List of America’s Best Startup Employers

Saama Redefines the Future of Clinical Development with Groundbreaking GenAI and Collaborative Platform Enhancements

©2025 McKesson Ventures | Privacy Notice | Disclaimer
  • Follow
  • Follow